Viatorr Endoprosthesis
Contact W. L. Gore & Associates, Inc. ↗ Compare similar devices
FDA Clearance Information
The Viatorr Endoprosthesis was cleared by the FDA via the 510(k) pathway on March 7, 2003. It is manufactured by W.L. Gore & Associates and classified as a Class 2 device.
What It Is
FDA-Cleared Indications
- For use in creating and maintaining a transjugular intrahepatic portosystemic shunt (TIPS).
- For treating portal venous hypertension when a TIPS procedure is clinically indicated.
- For maintaining shunt patency by providing a covered passage between the portal and hepatic venous systems.
Clinical Applications
- TIPS creation for portal hypertension.
- Reduction of portal pressure in selected patients with complications of portal hypertension.
- Management of variceal bleeding when TIPS is indicated.
- Treatment of selected portal-hypertension complications requiring a durable intrahepatic portosystemic channel.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- The device is deployed through venous access, typically through the internal jugular vein, using fluoroscopic and contrast imaging guidance.
- Device diameter and length must be selected to match the hepatic and portal venous anatomy and the planned shunt tract.
- The covered and uncovered portions must be positioned correctly so that the portal vein and hepatic vein remain patent while the hepatic parenchymal tract is lined.
- MRI safety and scanning conditions should be confirmed in the current manufacturer labeling before imaging. The implant may be subject to specific field-strength, spatial-gradient and heating limits.
- TIPS may be unsuitable or require special evaluation in patients with severe liver failure, significant heart failure, uncontrolled infection, severe pulmonary hypertension or other contraindications to portosystemic shunting.
Frequently Asked Questions
What are the clinical indications for Viatorr Endoprosthesis?
The Viatorr Endoprosthesis is indicated for use in TIPS procedures to manage portal hypertension and related complications.
What outcomes have been reported in clinical studies?
Studies report effective maintenance of shunt patency and improved outcomes in managing venous steno-occlusive disease.
What complications have been reported?
Safety data indicate risks of hepatic encephalopathy and deployment issues, necessitating careful clinical management.